Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 3/20 | 0.80 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.80 |
| ▸ | AMD1 | P17707 | 4/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | GAPDH | P04406 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HBB | P68871 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16805420 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL15906300 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL967122 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL1135195 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL15906323 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL18858928 | 1.00 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL21283085 | 0.91 | AMD1 (0.67) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL16378774 | 0.90 | AMD1 (0.77) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL952452 | 0.89 | AMD1 (0.76) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL952454 | 0.89 | AMD1 (0.76) | HSPA8HSPA5AMD1RXFP1GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223593-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2025-07-10 | — | — | US | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-11851656-B2 | Chemically modified single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2023-12-26 | — | — | US | claimed |
| CN-110352244-B | Chemically modified RNA editing single stranded oligonucleotides | ProQR治疗上市公司Ⅱ | 2023-03-21 | — | — | CN | claimed |
| US-20210238597-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2021-08-05 | — | — | US | claimed |
| US-10941402-B2 | Chemically modified single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2021-03-09 | — | — | US | claimed |
| EP-3507366-B1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II BV (NL) | 2020-10-07 | — | — | EP | claimed |
| CN-110352244-A | The single-stranded oligonucleotide of the editor RNA of chemical modification | ProQR治疗上市公司Ⅱ | 2019-10-18 | — | — | CN | claimed |
| US-20190218552-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2019-07-18 | — | — | US | claimed |
| EP-3507366-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | ProQR Therapeutics II B.V. (NL) | 2019-07-10 | — | — | EP | claimed |
| WO-2018041973-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2018-03-08 | — | — | WO | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612658-B2 | RNA replication using transcription polymerases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2003051881-A1 | SUBSTITUTED PURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS BY SOLID-PHASE COMBINATORIAL STRATEGIES | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030105052-A1 | Oligoribonucleotide derivatives for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2003008595-A2 | NOVEL OLIGORIBONUCLEOTIDE DERIVATIVES FOR THE TARGETED INHIBITION OF GENE EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003008576-A2 | SYNTHETIC DOUBLE STRANDED OLIGONUCLEOTIDES FOR TARGETED INHIBITION OF GENE EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105052-A1 | Oligoribonucleotide derivatives for specific inhibition of gene expression | RNGTT, DCLRE1B, POLI | HSPA8 569/4885HSPA5 1732/4885AMD1 1385/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | HSPA8 1345/4885HSPA5 1076/4885AMD1 1698/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | HSPA8 1831/4885HSPA5 4180/4885AMD1 2964/4885 |
| US-12612658-B2 | RNA replication using transcription polymerases | RNGTT, POLRMT, POLM | HSPA8 2281/4885HSPA5 1969/4885AMD1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.